NovelStem Increases NewStem Ownership to 33% as NewStem Preps for 1H'21 FDA Filing for Approval of Stem-Cell Based Anti-Cancer Drug Resistance Diagnostic; Initiates Process to Be Publicly Reporting...
The original release is unavailable here.
Earlier from Novelstem International
- NovelStem Announces New Research Collaborations for Stem-Cell Technology Platform in Cancer Immunotherapy & COVID-19 Resistance; Progress ID'ing Genetic Resistance to Addt'l Anti-Cancer Treatments
- NovelStem Increases NewStem Ownership to 27.3% Following Achievement of Development Milestones for Stem-Cell-Based Cancer Treatments Resistance Diagnostic
- NovelStem Provides Shareholder Update
- Hollywood Media Changes Name and Stock Symbol to NovelStem International Corp. and “NSTM” to Reflect Focus on Stem Cell-Based Diagnostics to Better Select Cancer Chemotherapies